Iovance Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Iovance Biotherapeutics

06/08/2026 14:32

Iovance Biotherapeutics Inc IOVA.OQ reported a quarterly adjusted loss of 11 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -33 cents.  The mean expectation of nine analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -16 cents to -6 cents per share.
Revenue rose 65.7% to $99.31 million from a year ago; analysts expected $87.83 million. 
Iovance Biotherapeutics Inc shares had risen by 4.3% this quarter and gained 59.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 2% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $9.00, about 51.8% above its last closing price of $4.34
This summary was machine generated from LSEG data August 6 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.13
-0.11
Beat
Mar. 31 2026 
-0.15
-0.19
Missed
Dec. 31 2025 
-0.17
-0.18
Missed
Sep. 30 2025 
-0.26
-0.25
Beat